Comprehensive Metabolomic Characterization of Coronary Artery Diseases
| Autor: | Lian-Wen Qi, Wei Zhu, Jin Li, Raphael N. Alolga, Yan Chen, Shi-Lei Wang, Yong Li, Guo-Ping He, Yong Fan, Fan-Qi Meng, Hao Xu, Yin Yin, Xiang-Ming Wang, Dong-Sheng Zhao, Jian-Hua Shen, Yi-Jing Zhao, Li-Wei Liu, Ping Li, Xin Zhou, Mao-De Lai |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Acute coronary syndrome medicine.medical_specialty medicine.drug_class Coronary Artery Disease 030204 cardiovascular system & hematology Angina Coronary artery disease 03 medical and health sciences 0302 clinical medicine Metabolomics Internal medicine medicine Humans cardiovascular diseases Myocardial infarction Coronary atherosclerosis Aged Bile acid Unstable angina business.industry Middle Aged medicine.disease 030104 developmental biology Endocrinology Cardiology Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of the American College of Cardiology. 68:1281-1293 |
| ISSN: | 0735-1097 |
| Popis: | Background Pathogenesis and diagnostic biomarkers for diseases can be discovered by metabolomic profiling of human fluids. If the various types of coronary artery disease (CAD) can be accurately characterized by metabolomics, effective treatment may be targeted without using unnecessary therapies and resources. Objectives The authors studied disturbed metabolic pathways to assess the diagnostic value of metabolomics-based biomarkers in different types of CAD. Methods A cohort of 2,324 patients from 4 independent centers was studied. Patients underwent coronary angiography for suspected CAD. Groups were divided as follows: normal coronary artery (NCA), nonobstructive coronary atherosclerosis (NOCA), stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI). Plasma metabolomic profiles were determined by liquid chromatography–quadrupole time-of-flight mass spectrometry and were analyzed by multivariate statistics. Results We made 12 cross-comparisons to and within CAD to characterize metabolic disturbances. We focused on comparisons of NOCA versus NCA, SA versus NOCA, UA versus SA, and AMI versus UA. Other comparisons were made, including SA versus NCA, UA versus NCA, AMI versus NCA, UA versus NOCA, AMI versus NOCA, AMI versus SA, significant CAD (SA/UA/AMI) versus nonsignificant CAD (NCA/NOCA), and acute coronary syndrome (UA/AMI) versus SA. A total of 89 differential metabolites were identified. The altered metabolic pathways included reduced phospholipid catabolism, increased amino acid metabolism, increased short-chain acylcarnitines, decrease in tricarboxylic acid cycle, and less biosynthesis of primary bile acid. For differential diagnosis, 12 panels of specific metabolomics-based biomarkers provided areas under the curve of 0.938 to 0.996 in the discovery phase (n = 1,086), predictive values of 89.2% to 96.0% in the test phase (n = 933), and 85.3% to 96.4% in the 3-center external sets (n = 305). Conclusions Plasma metabolomics are powerful for characterizing metabolic disturbances. Differences in small-molecule metabolites may reflect underlying CAD and serve as biomarkers for CAD progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|